Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Comment by fairweather1on Apr 11, 2013 6:34am
203 Views
Post# 21240221

RE: best use of resources

RE: best use of resources

I would change option 3 to "diversify" business.  I sincerely believe that mgt is working hard at diversification, and I think some people here don't realize the magnitude in the shift of the auto industry.  IF they manage to get an extension of Ford it will probably be less lucrative, and it may well be the last one for AM.

 

They have one contract good for another 12 months...share price is heavily tied to current cash reserves with some spec premium for possible new business.  I would continue the dividend at current levels until new business is found.  It makes more sense to spend your own cash on -- for instance -- a new wind power plant than borrowing for the plant.  Once they have some more solid contracts, I would ratchet up options 1 or 2.

In other words, I am very cautious with cash for now, but if things fell into place:

  • Ford extension -- though less lucrative
  • new wind or other temporary contract
  • at least partial (say half) settlement of GM litigation

I could see huge special dividends ... like $1 per share wouldn't be out of the question.

 

 

Bullboard Posts